DARA Biosciences (NASDAQ: DARA) is expecting to hear soon on the status of its Orphan Drug application submitted to The Food and Drug Administration (FDA) in November of last year for its drug KRN5500, which is being studied for the…
Tag: biopharma
4 Small Cap Biopharmas With Near-Term Catalysts
To begin this week, I list four biopharma companies I feel have significant catalysts coming up. According to investinganswers.com a catalyst is defined as news or information that changes a pricing trend in a security. Catalysts can drive an investment…
Pozen: An Undervalued Investment And Catalyst Trade Opportunity
Small cap biopharmas that make for good long term investments are hard to find. Most small cap biopharmas burn a ton of cash while developming treatments for a variety of ailments and rare diseases. Today, we focus on Pozen (NASDAQ:POZN)…
The Obesity Epidemic – EnteroMedics New Treatment Approach
Our focus turns to EnteroMedics (NASDAQ:ETRM), which offers a new treatment approach currently in Phase III clinical trials, designed to help morbidly obese people lose weight. EnteroMedics’ approach may be a better solution for people who see little or no…
Weekend Update: $CORT $ATHX $CLSN $BLRX $NEPT + Chart Analysis And Explanation
In this video, I review a couple of charts, and review a couple of my trade calls. Chart analysis and explanation offered. Hope you find the video educational! Scott
CORRECTED CHARTS: Chart and commentary on $ATHX and others + Trading Technicals
Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. Honoring Dr. King by following his example of looking at a…
Charts and commentary on $ATHX and others + Trading analysis. Honor Dr. King today.
Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. please note; the charts on the right side get cut off…
Athersys, Inc. (ATHX) Beginning Due Diligence (chart technicals to come in seperate post)
Beginning points of Due Diligence for Athersys (ATHX) I am long the stock from $1.24. My Short Term catalyst Price Target opinion is $1.55 to $1.75, and $2.75 based on if positive Phase II data is reported. Multiple 2013 Catalysts…
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers (Video)
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers commentary. YouTube Video, enjoy!
Neptune’s Bounce Should Continue: $3 in range
Originally posted at www.biomedreports.com Updated by StockMatusow.com Twitter @BioMedReports @ScottMatusow Neptune Technologies & Bioressources announced they will hold a conference call on Thursday, January 17th at 4:30 EST. The reason given for the call will be to discuss the third…
